Dataset Information

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study.

ABSTRACT: Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-directed treatments on the course of COVID-19. We conducted a retrospective, international study, collectively including 941 patients with CLL and confirmed COVID-19. Data from the beginning of the pandemic until March 16, 2021, were collected from 91 centers. The risk factors of case fatality rate (CFR), disease severity, and overall survival (OS) were investigated. OS analysis was restricted to patients with severe COVID-19 (definition: hospitalization with need of oxygen or admission into an intensive care unit). CFR in patients with severe COVID-19 was 38.4%. OS was inferior for patients in all treatment categories compared to untreated (p < 0.001). Untreated patients had a lower risk of death (HR = 0.54, 95% CI:0.41-0.72). The risk of death was higher for older patients and those suffering from cardiac failure (HR = 1.03, 95% CI:1.02-1.04; HR = 1.79, 95% CI:1.04-3.07, respectively). Age, CLL-directed treatment, and cardiac failure were significant risk factors of OS. Untreated patients had a better chance of survival than those on treatment or recently treated.

SUBMITTER: Chatzikonstantinou T

PROVIDER: S-EPMC8559135 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study.

Chatzikonstantinou Thomas T Kapetanakis Anargyros A Scarfò Lydia L Karakatsoulis Georgios G Allsup David D Cabrero Alejandro Alonso AA Andres Martin M Antic Darko D Baile Mónica M Baliakas Panagiotis P Bron Dominique D Capasso Antonella A Chatzileontiadou Sofia S Cordoba Raul R Correa Juan-Gonzalo JG Cuéllar-García Carolina C De Paoli Lorenzo L De Paolis Maria Rosaria MR Del Poeta Giovanni G Demosthenous Christos C Dimou Maria M Donaldson David D Doubek Michael M Efstathopoulou Maria M Eichhorst Barbara B El-Ashwah Shaimaa S Enrico Alicia A Espinet Blanca B Farina Lucia L Ferrari Angela A Foglietta Myriam M Frederiksen Henrik H Fürstenau Moritz M García-Marco José A JA García-Serra Rocío R Gentile Massimo M Gimeno Eva E Glenthøj Andreas A Gomes da Silva Maria M Gutwein Odit O Hakobyan Yervand K YK Herishanu Yair Y Hernández-Rivas José Ángel JÁ Herold Tobias T Innocenti Idanna I Itchaki Gilad G Jaksic Ozren O Janssens Ann A Kalashnikova Оlga B ОB Kalicińska Elżbieta E Karlsson Linda Katharina LK Kater Arnon P AP Kersting Sabina S Labrador Jorge J Lad Deepesh D Laurenti Luca L Levin Mark-David MD Lista Enrico E Lopez-Garcia Alberto A Malerba Lara L Marasca Roberto R Marchetti Monia M Marquet Juan J Mattsson Mattias M Mauro Francesca R FR Milosevic Ivana I Mirás Fatima F Morawska Marta M Motta Marina M Munir Talha T Murru Roberta R Niemann Carsten U CU Rodrigues Raquel Nunes RN Olivieri Jacopo J Orsucci Lorella L Papaioannou Maria M Pavlovsky Miguel Arturo MA Piskunova Inga I Popov Viola Maria VM Quaglia Francesca Maria FM Quaresmini Giulia G Qvist Kristian K Reda Gianluigi G Rigolin Gian Matteo GM Ruchlemer Rosa R Saghumyan Gevorg G Shrestha Amit A Šimkovič Martin M Špaček Martin M Sportoletti Paolo P Stanca Oana O Stavroyianni Niki N Tadmor Tamar T Te Raa Doreen D Tonino Sanne H SH Trentin Livio L Van Der Spek Ellen E van Gelder Michel M van Kampen Roel R Varettoni Marzia M Visentin Andrea A Vitale Candida C Wasik-Szczepanek Ewa E Wróbel Tomasz T San Segundo Lucrecia Yáñez LY Yassin Mohamed M Coscia Marta M Rambaldi Alessandro A Montserrat Emili E Foà Robin R Cuneo Antonio A Stamatopoulos Kostas K Ghia Paolo P

Leukemia 20211101 12

Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-directed treatments on the course of COVID-19. We conducted a retrospective, international study, collectively including 941 patients with CLL and confirmed COVID-19. Data from the beginning of the pandemic until March 16, 2021, were collected from 91 ...[more]

PMID: 34725454

Similar Datasets

Project description:BackgroundPatients with chronic lymphocytic leukemia (CLL) have a higher risk of developing other malignancies (OMs) compared to the general population. However, the impact of CLL-related risk factors and CLL-directed treatment is still unclear and represents the focus of this work.MethodsWe conducted a retrospective international multicenter study to assess the incidence of OMs and detect potential risk factors in 19,705 patients with CLL, small lymphocytic lymphoma, or high-count CLL-like monoclonal B-cell lymphocytosis, diagnosed between 2000 and 2016. Data collection took place between October 2020 and March 2022.FindingsIn 129,254 years of follow-up after CLL diagnosis, 3513 OMs were diagnosed (27.2 OMs/1000 person-years). The most common hematological OMs were Richter transformation, myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Non-melanoma skin (NMSC) and prostate cancers were the most common solid tumors (STs).The only predictor for MDS and AML development was treatment with fludarabine and cyclophosphamide with/without rituximab (FC ± R) (OR = 3.7; 95% CI = 2.79-4.91; p < 0.001). STs were more frequent in males and patients with unmutated immunoglobulin heavy variable genes (OR = 1.77; 95% CI = 1.49-2.11; p < 0.001/OR = 1.89; 95% CI = 1.6-2.24; p < 0.001).CLL-directed treatment was associated with non-melanoma skin and prostate cancers (OR = 1.8; 95% CI = 1.36-2.41; p < 0.001/OR = 2.11; 95% CI = 1.12-3.97; p = 0.021). In contrast, breast cancers were more frequent in untreated patients (OR = 0.17; 95% CI = 0.08-0.33; p < 0.001).Patients with CLL and an OM had inferior overall survival (OS) than those without. AML and MDS conferred the worst OS (p < 0.001).InterpretationOMs in CLL impact on OS. Treatment for CLL increased the risk for AML/MDS, prostate cancer, and NMSC. FCR was associated with increased risk for AML/MDS.FundingAbbVie, and EU/EFPIAInnovative Medicines Initiative Joint Undertaking HARMONY grant n° 116026.

Project description:Introduction The most dreaded pandemic grappling world now, the Coronavirus Disease 2019 (COVID-19), chiefly involves the respiratory system; nevertheless, it is a multisystem disorder. Its involvement of the hepatic system is considerable; however, still emerging are its clinical implications and effects on morbidity and mortality. The aim of this study is to report on the various aspects of its hepatic involvement by describing the alterations in tests of liver function and its significance in the disease outcome in a cohort of hospitalized COVID-19 patients at a tertiary centre in northern India. Methods This is a retrospective cohort study conducted in a tertiary-care hospital in northern India. All confirmed hospitalized COVID-19 cases aged 15 and above from Apr till Oct 2020 with no pre-existing liver disease were included. The primary endpoint was death at 28 days. Statistical analysis included descriptive analysis, sensitivity-specificity, and univariable and multivariable regression analysis as well as survival analysis. Results A total of 708 COVID-19 patients fulfilled the inclusion criteria included 561 (79.2%) males and 147 (20.8%) females. The median age was 49 (IQR=25) years. Mild and moderate/severe disease were seen in 508 (71.8%) and 200 (28.2) patients respectively. Serum bilirubin, Aspartate-aminotransferase (AST) and Alanine-aminotransferase (ALT) were elevated in 6.92%, 69.91% and 80.22% of patients respectively. In univariable logistic regression, AST [odds ratio; OR 1.008 95% CI (1.005-1.012) per 1 IU/L increase] and ALT [OR 1.005 95% CI (1.002-1.007) per 1 IU/L increase] were significantly associated with the odds of moderate-to-severe disease but only AST was significant after adjustment to age, sex, and comorbidity [adjusted odds ratio; aOR 1.007 95% CI (1.003-1.011) per 1IU/L increase]. Serum albumin was negatively associated with the odds of moderate to severe disease and remained significant in the adjusted model [aOR 0.217 95%CI (0.149-0.316) per 1g/dL increase]. Ninety-six patients succumbed to illness [case fatality rate; CFR 13.6%). In adjusted Cox Proportional-Hazards Model for mortality, AST [adjusted hazard ratio; aHR 1.002 95% CI (1.000-1.003) per 1 IU/L increase] and serum albumin [aHR 0.396 95% CI (0.285-0.549) per 1g/dL increase] showed significant association with mortality. Conclusion Liver function abnormalities are common in COVID 19 patients. In particular, AST and serum albumin levels are effective predictors of disease severity and mortality and can be used as markers of fatal disease in the management as well as prognostication of COVID-19.

Dataset Information

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study.

Publications

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets